Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Akcea
Akcea
Nearly 70% of Akcea's workforce is on the chopping block as Ionis executes major restructuring
Endpoints
Tue, 04/6/21 - 11:04 pm
Akcea
Ionis
layoffs
Sobi
Ionis, Akcea boosted by a positive PhII for their Novartis castoff cardio drug — and they plan to push ahead into pivotals
Endpoints
Wed, 01/22/20 - 11:00 am
Novartis
Akcea
Medco
AKCEA-APOCIII-LRx
antisense
Upcoming events – Karyopharm's myeloma expansion and Pfizer's biz dev news
EP Vantage
Sun, 01/5/20 - 07:11 pm
Karyopharm
Xpovio
Multiple Myeloma
Pfizer
Akcea
Ionis Pharmaceuticals
AKCEA-ANGPTL3-Lrx
Novartis elects to keep one heart drug, discard the other from option deal with Akcea, Ionis
Endpoints
Thu, 12/19/19 - 12:51 pm
Novartis
Akcea
Ionis
AKCEA-APO(a)-L
ACEKA-APOCIII-L
Akcea, Fresh Off C-Suite Shakeup, Dishes Heart Drug to Pfizer for $250M
Xconomy
Mon, 10/7/19 - 11:18 am
Pfizer
Akcea
Ionis Pharmaceuticals
heart disease
AKCEA-ANGPTL3-Lrx
The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate
Yahoo/Benzinga
Sun, 07/28/19 - 11:48 pm
biotech
earnings
Immunic
Alkermes
Conatus
Aevi Genomic
Tricida
Curis
Ultragenyx
Leap Therapeutics
Cidara Therapeutics
Akcea
Spark Therapeutics
Eli Lilly
AnaptysBio
clinical trials
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
Xconomy
Mon, 05/6/19 - 10:54 am
FDA
Pfizer
tafamidis
Vyndaqel
Vyndamax
ATTR
Alnylam
Akcea
AbbVie, Akcea benefit from latest CHMP recommendations
Biopharma Dive
Sun, 03/3/19 - 07:12 pm
Europe
CHMP
AbbVie
Akcea
Biomarin
Sanofi
Pfizer
drug approvals
Early November Brings More Quarterly Reports
BioSpace
Sun, 11/4/18 - 02:38 pm
earnings
Akcea
Mylan
Eli Lilly
Regeneron
FDA clears rare disease therapy from Akcea, Ionis
Biopharma Dive
Fri, 10/5/18 - 09:38 pm
FDA
Akcea
Ionis Pharmaceuticals
Tegsedi
Onpattro
Alnylam
hATTR amyloidosis
FDA Extends Action Date on Akcea's Inotersen, Alnylam Now in Lead
CP Wire
Fri, 05/4/18 - 09:58 am
Akcea
hereditary ATTR amyloidosis
FDA
inotersen
Alnylam
Patisiran
Ionis Sends Nerve Drug to Spinout Akcea as Battle with Alnylam Looms
Xconomy
Thu, 03/15/18 - 11:09 am
Ionis Pharmaceuticals
Akcea
Alnylam
transthyretin amyloidosis
inotersen
IONIS-TTR-Lrx
Ionis-spinout Akcea prices IPO below expected range
Drug Delivery Business News
Sat, 07/15/17 - 11:23 am
Akcea
Ionis
IPOs
Volanesorsen
Akcea now shooting for $200M-plus as a new lineup of biotech IPOs prep for a launch
Endpoints
Tue, 06/20/17 - 09:51 am
Akcea
biotech
IPOs
Novartis